Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $247 | In Stock | |
5 mg | $647 | In Stock | |
10 mg | $987 | In Stock |
Description | Carotuximab (DE-122) is a novel endocholine antibody with strong antiangiogenic and anti-inflammatory activity. Carotuximab blocks endothelial glycoprotein (CD105) and its downstream Smad signaling pathway. Carotuximab has immunomodulatory and antitumor effects to prevent human endothelial dysfunction induced by hypercholesterolemia and hyperglycemia. |
In vitro | In human aortic endothelial cells, pretreatment with Carotuximab (TRC105) at a concentration of 300 μg/mL for 1 hour, followed by co-culture for 12 hours, resulted in the reduction of 7-ketocholesterol-induced endothelial glycoprotein (Eng) protein levels. Additionally, Carotuximab inhibited the pSmad1/5 and pSmad2/3 signaling pathways. The blockade of Eng by Carotuximab prevented 7-ketocholesterol-induced monocyte adhesion and migration through endothelial monolayer cells [1]. |
In vivo | In acute myeloid leukemia (AML) xenografts, the combination of Carotuximab (TRC105) and Decitabine, administered intravenously at a dose of 2 mg/kg once every 3 days for 8 weeks, produces a more durable anti-leukemia effect. Additionally, this combination enhances reactive oxygen species (ROS) activity [2]. |
Alias | DE-122, TRC105 |
Cas No. | 1268714-50-6 |
Storage | store at low temperature | store at -80°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.